aureus, a core microbial driver of atopic dermatitis, offering a potential novel avenue for treatment. "We are thrilled to have our first participant enrolled," said Chief Executive Officer Cheri ...

Aclaris Therapeutics has secured an exclusive license from Biosion for the global rights to two new antibodies.

Aclaris (ACRS) soared 60% Tuesday, the day after the company announced it was licensing two drug candidates, prompting ...

BTIG upgraded Aclaris Therapeutics (ACRS) to Buy from Neutral with an $8 price target In a “transformative transaction,” Aclaris has acquired full ex-China rights to an anti-TSLP humanized mAb and ...

The CDA-AMC recommended that Ebglyss not be reimbursed by public drug plans, excluding Quebec, for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years of age and ...

Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on November 11.Don't Miss our Black ...

Therefore, even individuals without childhood eczema may experience it later in life. Dr Grant has debunked the common ...

The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its ...

Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned ...

Aclaris stock surges on inking an exclusive license agreement with Biosion for global rights to two of the latter's pipeline candidates, BSI-045B and BSI-502.

The US Food and Drug Administration (FDA) has accepted a resubmission of the supplemental Biologics License Application for ...